Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943475 | 0.87 | CHRM2 (0.63) | CHRM2CHRM3 | |
| SCHEMBL6102523 | 0.86 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL942051 | 0.86 | CHRM2 (0.62) | CHRM2CHRM3 | |
| SCHEMBL644642 | 0.85 | CHRM2 (0.60) | CHRM2CHRM3 | |
| SCHEMBL644264 | 0.84 | CHRM2 (0.60) | CHRM2CHRM3 | |
| SCHEMBL1303373 | 0.84 | CHRM2 (0.75) | CHRM2CHRM3 | |
| SCHEMBL643300 | 0.83 | CHRM2 (0.58) | CHRM2CHRM3 | |
| SCHEMBL1302647 | 0.81 | CHRM2 (0.55) | CHRM2CHRM3 | |
| SCHEMBL3759672 | 0.80 | CHRM3 (0.59) | CHRM2CHRM3 | |
| SCHEMBL3766100 | 0.79 | CHRM2 (0.57) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868175-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7629336-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((4-[4-(2-hydroxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.